Understanding participation in Merkel cell carcinoma trials
Part of Cancer, Infections clinical trials.
This study looks at how people with Merkel cell carcinoma take part in clinical trials. It helps researchers understand what helps or makes it hard for patients to join and stay in studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with Merkel cell carcinoma.
- You can understand the study and give your permission to join.
- You can use a computer, tablet, or smartphone to regularly share your health information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for Merkel cell carcinoma cells in the blood before and after surgery (and/or radiation). It may help researchers understand how these cells change with treatment.
This trial tests the combination of pembrolizumab (an immunotherapy) with standard chemotherapy (cisplatin or carboplatin plus etoposide) in people with advanced Merkel cell carcinoma who haven't had treatment before. The goal is to see if this combination improves outcomes.
This trial tests pembrolizumab (an immune therapy) given before surgery to shrink Merkel cell carcinoma and improve outcomes. Participants also have extra tumor biopsies to study biomarkers, which may help explain who benefits most.
This trial tests a combination of two immunotherapy drugs, nivolumab and relatlimab, before surgery for Merkel cell carcinoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This Phase 2 trial studies whether peptide receptor radionuclide therapy (targeted radiation) combined with immunotherapy (pembrolizumab) can shrink Merkel cell cancer after it has grown despite anti–PD-1/L1 treatment. It may help people whose cancer has specific receptors that make them eligible for the targeted radiation.
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Hear when a new Merkel Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.